Physician profile
Avery Carter
NPI 1114414489
$2,537.59
in general payments reported to CMS, 2019-2025
22 companies · $733 in 2025
The $733 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $521 · 2023: $399 · 2024: $648 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $377.60 | 2022-2024 | Impella |
| Abbott Laboratories | $364.49 | 2023-2025 | Cardiomems, Dragonfly Opstar, Aveir |
| E.R. Squibb & Sons, L.L.C. | $328.97 | 2022-2025 | Camzyos |
| Medtronic, INC. | $263.20 | 2024-2025 | Corevalve Evolut R, Cobalt Dr Mri Surescan |
| Astrazeneca Pharmaceuticals Lp | $222.16 | 2021-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $188.75 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.09 | 2022-2024 | Lifevest |
| Abbvie INC. | $124.98 | 2025 | |
| Insmed, INC. | $118.65 | 2022 | |
| Glaxosmithkline, LLC. | $117.76 | 2021 | |
| Merck Sharp & Dohme LLC | $53.00 | 2023-2025 | Capvaxive, Verquvo, Recarbrio |
| Amgen INC. | $37.31 | 2023-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $29.61 | 2025 | Ams 800 Artificial Urinary Sphincter |
| Terumo Medical Corporation | $24.01 | 2024 | Metacross Otw |
| Alnylam Pharmaceuticals INC. | $22.37 | 2025 | Amvuttra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.02 | 2023 | Xarelto |
| Baxter Healthcare | $21.98 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Pfizer INC. | $21.59 | 2023 | |
| Cardiva Medical, INC. | $20.49 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.64 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $16.47 | 2025 | |
| Teleflex LLC | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.